This study investigated the effects of oral recombinant methioninase (o-rMETase) supplementation on PSA levels in two advanced prostate cancer patients. The results showed promising reductions in PSA levels, with one patient experiencing a 38% reduction and the other a 20% reduction after one month of supplementation. These findings suggest that
This systematic review and meta-analysis evaluated the efficacy and safety of non-steroidal antiandrogen (NSAA) monotherapy compared to luteinising hormone-releasing hormone (LHRH) agonists or surgical castration in advanced prostate cancer. The study found that NSAA monotherapy was associated with a higher risk of death (HR 1.25, 95% CI 1.05-1.48), increased clinical
This systematic review evaluated the effectiveness and cost-effectiveness of various androgen suppression therapies for advanced prostate cancer, comparing monotherapy options such as orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonists, and antiandrogens to combined androgen blockade (CAB), while also examining the timing of therapy initiation (immediate vs. deferred). The study found that
